Tallimustine in advanced previously untreated colorectal cancer, a phase II study
Authors:
- Y HumbletYHY Humblet
- E RocaERE Roca
- Ly DirixLDLy Dirix
- R WainsteinRWR Wainstein
- A PolliAPA Polli
- I CorradinoICI Corradino
Open Access
- 1 March 1996
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 73 (6) , 803-804
Abstract
Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of action. It is a DNA minor groove binder and produces highly sequence-specific alkylations. Previous studies have shown significant anti-tumour effects in animal models. We performed a phase II study in previously untreated patients with advanced colorectal cancer, using a schedule of i.v. bolus infusions of 900 microgram m-2 once every 4 weeks. Seventeen patients were enrolled, and no responses were documented in 14 evaluable patients. Toxicity mainly consisted a highly selective neutropenia, which warrants further investigation of this agent in combination with myeloid growth factors.Keywords
This publication has 10 references indexed in Scilit:
- DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycinNucleic Acids Research, 1995
- Phase I study of the novel distamycin derivative tallimustine (FCE 24517)Annals of Oncology, 1994
- Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517)British Journal of Cancer, 1993
- The effects of a benzoic acid mustard derivative of distamycin a (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agentsBiochemical Pharmacology, 1993
- Establishment of l1210 leukemia cells resistant to the distamycin‐a derivative (FCE 24517): Characterization and cross‐resistance studiesInternational Journal of Cancer, 1993
- The unique interaction with immunity of FCE 24517, an antitumor drug with a novel mode of actionInternational Journal of Immunopharmacology, 1992
- Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin ABritish Journal of Cancer, 1991
- Selective DNA interaction of the novel distamycin derivative FCE 24517.1991
- Specific inhibition of human DNA ligase adenylation by a distamycin derivative possessing antitumor activityNucleic Acids Research, 1991
- Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivativesJournal of Medicinal Chemistry, 1989